Leukemia, Myelogenous, Chronic, BCR-ABL Positive: all 982 studies
Page 8 of 10. Open to participants first (109), then studies with results posted, then the rest; newest registration first within each.
- Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world SettingCompletedNCT01244750
- Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND OptimisationCompletedNCT01243489Phase 4
- MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
- A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid LeukemiaCompletedNCT01227356Phase 2
- Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid LeukemiaStatus unknownNCT01227135Phase 2
- To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of NilotinibCompletedNCT01223898Phase 1
- Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)Status unknownNCT01221376Phase 2
- Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)CompletedNCT01220648Phase 1
- A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With ImatinibCompletedNCT01215487
- AHN-12 Biodistribution in Advanced LeukemiaTerminatedNCT01207076Phase 1
- Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell TransplantNo longer availableNCT01200017
- RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.WithdrawnNCT01188889Phase 1/2
- Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure SurveyCompletedNCT01188278
- High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
- Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic MalignanciesCompletedNCT01175785Phase 2
- Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)CompletedNCT01167166Phase 1/2
- T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic MalignanciesWithdrawnNCT01163201Phase 1/2
- Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid LeukemiaTerminatedNCT01159301Phase 1
- Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced LeukemiasCompletedNCT01149915Phase 1
- Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.TerminatedNCT01130688Phase 1
- A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic PhaseCompletedNCT01126892Phase 3
- Impact of the Inhibitors of Tyrosine Kinase on the Male FertilityCompletedNCT01114087Not applicable
- ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic MalignanciesCompletedNCT01110473Phase 1
- Late Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT01092741Phase 2
- Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic SyndromeCompletedNCT01075425Phase 1
- Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-AlphaTerminatedNCT01073436
- A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell TransplantationCompletedNCT01068301Phase 1
- Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.TerminatedNCT01066468Phase 1
- Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid MalignanciesCompletedNCT01056614Phase 2
- Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerCompletedNCT01053494Not applicable
- Symptom Burden in Chronic Myeloid Leukemia (CML)Status unknownNCT01046305
- MSC and HSC Coinfusion in Mismatched MinitransplantsTerminatedNCT01045382Phase 2
- Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell TransplantationCompletedNCT01020175Phase 3
- Unrelated Double Umbilical Cord Blood Units TransplantationStatus unknownNCT01015742Phase 2/3
- A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)WithdrawnNCT01011998Phase 2
- Autologous Transplantation for Chronic Myelogenous LeukemiaCompletedNCT01003054Phase 2
- Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic MalignancyCompletedNCT00990587Phase 1
- Intraosseous Infusion of Unrelated Cord Blood GraftsTerminatedNCT00967525Not applicable
- Allogeneic Stem Cell Transplantation in CML With Partial T Cell DepletionStatus unknownNCT00966810Phase 2/3
- Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and MyelomaCompletedNCT00965224Phase 2
- A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous LeukemiaCompletedNCT00964873Phase 1
- Investigating Intracellular and Plasma Imatinib Levels in Chronic Myeloid LeukemiaCompletedNCT00947830
- Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or LeukemiaTerminatedNCT00933985Phase 1
- Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic PhaseApproved for marketingNCT00905593
- Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line TherapyCompletedNCT00896129
- Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid LeukemiaTerminatedNCT00895297Phase 2
- Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
- A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid LeukemiaCompletedNCT00866736Phase 2
- PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic TransplantationWithdrawnNCT00866346Phase 1
- Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib TherapyCompletedNCT00858806Phase 2
- Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)CompletedNCT00854646Phase 1
- Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute LeukemiasTerminatedNCT00852709Phase 1
- Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid LeukemiaCompletedNCT00852566Phase 2
- Glivec in Pediatric Chronic Myeloid Leukemia (CML)CompletedNCT00845221Phase 4
- Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)CompletedNCT00827138Phase 1
- Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic LeukemiaCompletedNCT00816283Phase 1
- Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug TherapyCompletedNCT00815321Phase 2
- Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00809211Phase 2
- A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic MalignanciesCompletedNCT00807677Phase 1
- Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsCompletedNCT00799461Phase 3
- Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic PhaseCompletedNCT00786812Phase 4
- Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00769327Phase 2
- Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL PositiveCompletedNCT00763763Phase 2
- Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy SubjectsCompletedNCT00759837Phase 1
- Nilotinib Pre and Post Allogeneic Stem Cell TransplantationCompletedNCT00750659Phase 2
- Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid LeukemiaWithdrawnNCT00732186Phase 1
- Natural Killer Cells and Bortezomib to Treat CancerCompletedNCT00720785Phase 1
- A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid MalignanciesCompletedNCT00719836Phase 1/2
- CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide GeneActive, not recruitingNCT00710892Phase 1
- Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic MalignanciesCompletedNCT00697671Phase 1
- Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or MyelodysplasiaCompletedNCT00677859Phase 1
- Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell TransplantTerminatedNCT00674427Phase 1
- A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following TransplantationTerminatedNCT00672152Phase 1
- Phase 1 Study of Terameprocol (EM-1421) in Patients With LeukemiaTerminatedNCT00664677Phase 1
- Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to GleevecCompletedNCT00661180Phase 2
- Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological MalignanciesCompletedNCT00660920Phase 1
- Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to TreatmentCompletedNCT00632255
- Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric MalignanciesCompletedNCT00619879
- Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)Status unknownNCT00598624Phase 2
- A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid LeukemiaWithdrawnNCT00594555Phase 2
- Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative DisordersCompletedNCT00588991Phase 1
- Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal TumorsCompletedNCT00580281Not applicable
- Palifermin After Haploidentical PBSCTWithdrawnNCT00570999Phase 2
- Investigation of the Cylex® ImmuKnow® AssayCompletedNCT00569842
- A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid MalignanciesTerminatedNCT00569179Phase 1
- Prospective Database for Chronic Myelogenous LeukemiaStatus unknownNCT00538447Not applicable
- An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic PhaseCompletedNCT00538109Not applicable
- Reduced Intensity AlloSCT in(CML) With Persistent DiseaseTerminatedNCT00531310Phase 2
- Study to Assess the Safety of Escalating Doses of AT9283, in Patients With LeukemiasTerminatedNCT00522990Phase 1/2
- Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCTCompletedNCT00516152Phase 2
- Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic PhaseCompletedNCT00514969Phase 2
- Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic MalignanciesTerminatedNCT00514722Not applicable
- Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day)CompletedNCT00514488Phase 3
- Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic MalignanciesTerminatedNCT00513318
- Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic AnemiaCompletedNCT00513175
- Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid LeukemiaCompletedNCT00511303Phase 2
- Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)TerminatedNCT00511121Phase 2
- Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic PhaseCompletedNCT00510926Phase 2
- A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)TerminatedNCT00500006Phase 1
- Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00489203Phase 2